Suppressive effects of acid-forming diet against the tumorigenic potential of pioglitazone hydrochloride in the urinary bladder of male rats.
Pioglitazone hydrochloride (PIO), a peroxisome proliferator-activated receptor gamma (PPARγ) agonist, was administered orally for 85 weeks at 16 mg/kg/day to male rats fed either a diet containing 1.5% ammonium chloride (acid-forming diet) or a control diet to investigate the effects of urinary acidification induced by the acid-forming diet on the tumorigenic potential of PIO in the urinary bladder. The surviving animals at the end of the administration period were followed to the end of the 2-year study period without changes in the diet and were subjected to terminal necropsy on Week 104. The number of urinary microcrystals, evaluated by manual counting with light microscopy and by an objective method with a laser diffraction particle size analyzer, was increased by PIO on Weeks 12 and 25 and the increases were markedly suppressed by urinary acidification. Urinary citrate was decreased by PIO throughout the study period, but no changes were seen in urinary oxalate at any timepoint. The incidences of PIO-treated males bearing at least one of the advanced proliferative changes consisting of papillary hyperplasia, nodular hyperplasia, papilloma or carcinoma were significantly decreased from 11 of 82 males fed the control diet to 2 of 80 males fed the acid-forming diet. The acid-forming diet did not show any effects on the toxicokinetic parameters of PIO and its metabolites. Microcrystalluria appears to be involved in the development of the advanced stage proliferative lesions in bladder tumorigenesis induced by PIO in male rats.
Development Research Center, Takeda Pharmaceutical Company Limited, Osaka 532-8686, Japan. Sato_Keiichiro@takeda.co.jp
Keiichiro
K
Sato
Yasuyuki
Y
Awasaki
Hitoshi
H
Kandori
Zen-Yo
ZY
Tanakamaru
Hirofumi
H
Nagai
David
D
Baron
Masaki
M
Yamamoto
D000643:Ammonium Chloride / Q000008:administration & dosage*; D000818:Animals; D002951:Citrates / Q000652:urine; D004032:Diet; D006863:Hydrogen-Ion Concentration; D007004:Hypoglycemic Agents / Q000493:pharmacokinetics / Q000633:toxicity*; D007834:Lasers; D008297:Male; D008853:Microscopy; D010070:Oxalates / Q000652:urine; D047495:PPAR gamma / Q000819:agonists; D010316:Particle Size; D000077205:Pioglitazone; D051381:Rats; D017207:Rats, Sprague-Dawley; D045162:Thiazolidinediones / Q000493:pharmacokinetics / Q000633:toxicity*; D001743:Urinary Bladder / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D001749:Urinary Bladder Neoplasms / Q000139:chemically induced* / Q000517:prevention & control
D002951:Citrates; D007004:Hypoglycemic Agents; D010070:Oxalates; D047495:PPAR gamma; D045162:Thiazolidinediones; D000643:Ammonium Chloride; D000077205:Pioglitazone